2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2010
Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Reddy K, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin. Transplantation Proceedings 2010, 42: 2006-2008. PMID: 20692393, DOI: 10.1016/j.transproceed.2010.05.090.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumCreatinineDrug Therapy, CombinationGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMycophenolic AcidPancreas TransplantationPatient SelectionRetrospective StudiesConceptsRapid steroid taperAcute rejection episodesR-ATG groupR-ATGSimultaneous kidneySteroid taperBK nephropathyRejection episodesPancreas transplantationAlemtuzumab groupClinical acute rejection episodesRabbit antithymocyte globulin inductionAntithymocyte globulin inductionR-ATG inductionMean serum creatinineHistoric control groupPostoperative day 4Alemtuzumab inductionAntithymocyte globulinGlobulin inductionMaintenance immunosuppressionTransplant characteristicsGraft survivalCMV infectionCytomegalovirus infection
2009
Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2005
Immunosuppression in liver transplantation
Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transplantation 2005, 11: 1307-1314. PMID: 16237688, DOI: 10.1002/lt.20614.Peer-Reviewed Original Research
2004
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response
2002
A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation
Hellinger WC, Yao JD, Alvarez S, Blair JE, Cawley JJ, Paya CV, O’Brien P, Spivey JR, Dickson RC, Harnois DM, Douglas DD, Hughes CB, Nguyen JH, Mulligan DC, Steers JL. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation 2002, 73: 1904-1909. PMID: 12131685, DOI: 10.1097/00007890-200206270-00009.Peer-Reviewed Original ResearchConceptsSelective bowel decontaminationLiver transplantationRate of infectionDay 0Bowel decontaminationMedical careBacterial infectionsDouble-blinded fashionDouble-blinded evaluationGentamicin 80Mortal complicationsUncontrolled trialsSwab culturesTreatment groupsTransplantationPatientsDay 21Day 60Routine useInfectionPositive floraNegative floraFecal cultureCareDeath
1998
Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients
Post AB, Mulligan DC, Bush W. Cost analysis of four strategies for prevention of CMV infection in liver transplant recipients. Transplantation Proceedings 1998, 30: 2102-2103. PMID: 9723406, DOI: 10.1016/s0041-1345(98)00553-3.Peer-Reviewed Original Research
1997
Reduction of early rejection in adult liver transplantation with ATG induction therapy
Schulak J, May E, Post A, Fasola C, Mulligan D, Sterling R. Reduction of early rejection in adult liver transplantation with ATG induction therapy. Transplantation Proceedings 1997, 29: 555-556. PMID: 9123126, DOI: 10.1016/s0041-1345(96)00264-3.Peer-Reviewed Original Research